6L
6L8.F Pulse Biosciences Inc
- Market cap
- EUR 3.68B
- P/E
- -
- P/B
- 21.67x
- ROE
- -48.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 6L8.F undervalued?
Graham numberThe Graham number of Pulse Biosciences Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Pulse Biosciences Inc fundamental analysis
No fundamental analysis for Pulse Biosciences Inc yet.
Pulse Biosciences Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Pulse Biosciences Inc
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac Catheter System designed to provide a circumferential, or circular, ablation in…
Full company profilePulse Biosciences Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Pulse Biosciences Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.42M | 700K | 0.00 | 0.00 | 350K | 1.64M |
| Gross Profit | - | - | - | - | 0.00 | -550K | -11.2M | 0.00 | 0.00 | -189K | 528K |
| Operating Income | -9.59M | -25.8M | -38.0M | -48.0M | -50.0M | -63.0M | -58.1M | -43.6M | -56.3M | -76.9M | -91.6M |
| EBITDA | - | -24.8M | -36.7M | -46.8M | -48.9M | -61.9M | -56.7M | -42.4M | -55.1M | -75.9M | -90.6M |
| Net Income | -9.52M | -25.6M | -37.5M | -47.0M | -49.9M | -63.7M | -58.5M | -42.2M | -53.6M | -72.8M | -88.4M |
| EPS | - | -1.52 | -1.82 | -2.26 | -1.95 | -2.14 | -1.55 | -0.75 | -0.81 | -1.07 | -1.21 |
| Balance Sheet | |||||||||||
| Total Assets | 26.3M | 49.8M | 70.6M | 41.9M | 41.3M | 54.2M | 77.9M | 59.2M | 132M | 94.5M | 202M |
| Total Liabilities | 1.02M | 3.83M | 4.31M | 11.2M | 18.4M | 18.6M | 80.1M | 14.8M | 17.6M | 13.9M | 18.0M |
| Shareholders' Equity | 25.3M | 46.0M | 66.3M | 30.7M | 22.9M | 35.7M | -2.25M | 44.4M | 115M | 80.7M | 184M |
| Cash & Short-term Investments | 2.09M | 3.39M | 51.1M | 6.90M | 12.5M | 28.6M | 61.1M | 44.4M | 118M | 80.7M | 36.7M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -8.05M | -11.1M | -23.9M | -34.2M | -35.4M | -54.1M | -47.0M | -33.0M | -36.3M | -54.1M | -64.8M |
| Capital Expenditure | 64.0K | 2.55M | 276K | 608K | 441K | 437K | 401K | 121K | 125K | 335K | 353K |
| Free Cash Flow | - | -13.6M | -24.2M | -34.8M | -35.8M | -54.5M | -47.4M | -33.2M | -36.5M | -54.5M | -65.1M |
| Ratios | |||||||||||
| ROE | -37.6% | -55.6% | -56.6% | -152.8% | -217.7% | -178.4% | - | -95.2% | -46.7% | -90.2% | -48.1% |
| ROA | -36.2% | -51.3% | -53.1% | -112.1% | -120.7% | -117.3% | -75.1% | -71.4% | -40.5% | -77.0% | -43.8% |
| Net Profit Margin | - | - | - | - | - | -4,489.4% | -8,357.9% | - | - | -20,794.6% | -5,389.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Pulse Biosciences Inc dividends
Pulse Biosciences Inc has not paid dividends in the last 9 fiscal years.
Who owns Pulse Biosciences Inc
- Insiders 68.90%
- Institutions 14.86%
- Public & others 16.24%
- Shares outstanding 73.5M
- Free float 22.9M
Pulse Biosciences Inc company profile
- Company name
- Pulse Biosciences Inc
- Ticker
- 6L8.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 116
- Fiscal year end
- December
- Address
- 601 Brickell Key Drive, Miami, FL, United States, 33131
- Phone
- 510 906 4600
- Website
- pulsebiosciences.com
About Pulse Biosciences Inc
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac Catheter System designed to provide a circumferential, or circular, ablation in a single treatment cycle; and nPulse Console, a software-enabled console-based platform designed to accommodate the clinical workflow preferred by physicians. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Miami, Florida.
Pulse Biosciences Inc management
10- Mr. Paul Arthur LaViolette M.B.A.President, CEO & Co-Chairman of the Board · born 1958
- Mr. Jon SkinnerChief Financial Officer · born 1986
- Mr. Darrin R. UeckerCTO & Director · born 1966
- Ms. Liane TeplitskyChief Operating Officer · born 1977
- Mr. Steven T. WeberVP of Accounting, Principal Accounting Officer & Global Corporate Controller · born 1976
- Mr. Kenneth B. Stratton Esq., J.D.General Counsel & Corporate Secretary · born 1969
- Ms. Patty PerlaVice President of Human Resources
- Mr. David DanitzSenior Vice President of Engineering
- Dr. Gansevoort Dunnington M.D.Chief Medical Officer
- Dr. Niv Ad M.D.Chief Science Officer of Cardiac Surgery